bluebird bio (NASDAQ: BLUE) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare bluebird bio to similar businesses based on the strength of its earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Insider & Institutional Ownership
49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.9% of bluebird bio shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for bluebird bio and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|bluebird bio Competitors||924||3346||11852||237||2.70|
bluebird bio currently has a consensus price target of $159.53, suggesting a potential downside of 9.92%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.95%. Given bluebird bio’s rivals stronger consensus rating and higher probable upside, analysts plainly believe bluebird bio has less favorable growth aspects than its rivals.
Risk & Volatility
bluebird bio has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, bluebird bio’s rivals have a beta of 0.44, indicating that their average share price is 56% less volatile than the S&P 500.
Earnings and Valuation
This table compares bluebird bio and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|bluebird bio||$6.16 million||-$263.50 million||-25.26|
|bluebird bio Competitors||$290.27 million||$35.99 million||58.76|
bluebird bio’s rivals have higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares bluebird bio and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|bluebird bio Competitors||-5,189.81%||-162.78%||-35.24%|
bluebird bio rivals beat bluebird bio on 9 of the 13 factors compared.
About bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.